|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
|
US4496689A
(en)
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
|
EP0206448B1
(en)
|
1985-06-19 |
1990-11-14 |
Ajinomoto Co., Inc. |
Hemoglobin combined with a poly(alkylene oxide)
|
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
|
WO1993012227A1
(en)
|
1991-12-17 |
1993-06-24 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
US5625825A
(en)
|
1993-10-21 |
1997-04-29 |
Lsi Logic Corporation |
Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
|
|
JP4122056B2
(ja)
|
1995-04-06 |
2008-07-23 |
リジエネロン ファーマシューティカルズ，インコーポレイテッド |
Ｔｉｅ−２リガンド、その作製方法および使用方法
|
|
US6133426A
(en)
|
1997-02-21 |
2000-10-17 |
Genentech, Inc. |
Humanized anti-IL-8 monoclonal antibodies
|
|
KR100816621B1
(ko)
|
1997-04-07 |
2008-03-24 |
제넨테크, 인크. |
항-ｖｅｇｆ 항체
|
|
US7070959B1
(en)
|
1999-06-08 |
2006-07-04 |
Regeneron Pharmaceuticals, Inc. |
Modified chimeric polypeptides with improved pharmacokinetic properties
|
|
US6316109B1
(en)
|
2000-09-21 |
2001-11-13 |
Ppg Industries Ohio, Inc. |
Aminoplast-based crosslinkers and powder coating compositions containing such crosslinkers
|
|
CN1318093C
(zh)
|
2001-09-28 |
2007-05-30 |
参天制药株式会社 |
含与聚乙二醇结合的药物的眼组织注射剂
|
|
US20030158083A1
(en)
|
2002-02-08 |
2003-08-21 |
The Procter & Gamble Company |
Method of effecting angiogenesis by modulating the function of a novel endothelia phosphatase
|
|
US20030215899A1
(en)
|
2002-02-13 |
2003-11-20 |
Ceptyr, Inc. |
Reversible oxidation of protein tyrosine phosphatases
|
|
US7226755B1
(en)
|
2002-09-25 |
2007-06-05 |
The Procter & Gamble Company |
HPTPbeta as a target in treatment of angiogenesis mediated disorders
|
|
US7507568B2
(en)
|
2002-09-25 |
2009-03-24 |
The Proctor & Gamble Company |
Three dimensional coordinates of HPTPbeta
|
|
US7758859B2
(en)
|
2003-08-01 |
2010-07-20 |
Genentech, Inc. |
Anti-VEGF antibodies
|
|
US20050059639A1
(en)
|
2003-09-11 |
2005-03-17 |
Wei Edward T. |
Ophthalmic compositions and method for treating eye discomfort and pain
|
|
AU2005224091B2
(en)
|
2004-03-15 |
2012-02-02 |
Janssen Pharmaceutica, N.V. |
Novel compounds as opioid receptor modulators
|
|
CA2599606A1
(en)
|
2005-02-23 |
2006-08-31 |
Merrimack Pharmaceuticals, Inc. |
Bispecific binding agents for modulating biological activity
|
|
US20120237442A1
(en)
|
2005-04-06 |
2012-09-20 |
Ibc Pharmaceuticals, Inc. |
Design and Construction of Novel Multivalent Antibodies
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
US20070154482A1
(en)
|
2005-09-12 |
2007-07-05 |
Beth Israel Deaconess Medical Center |
Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
|
|
WO2007041317A2
(en)
|
2005-09-29 |
2007-04-12 |
Viral Logic Systems Technology Corp. |
Immunomodulatory compositions and uses therefor
|
|
EP1962903B1
(en)
|
2005-12-15 |
2013-03-13 |
MedImmune Limited |
Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer
|
|
EP1981520A2
(en)
|
2006-01-30 |
2008-10-22 |
(OSI) Eyetech, Inc. |
Combination therapy for the treatment of neovascular disorders
|
|
RU2494108C2
(ru)
|
2006-04-07 |
2013-09-27 |
Аерпио Терапетикс, Инк. |
Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование
|
|
CA2654510C
(en)
|
2006-06-16 |
2015-03-17 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonist formulations suitable for intravitreal administration
|
|
US7622593B2
(en)
|
2006-06-27 |
2009-11-24 |
The Procter & Gamble Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US7795444B2
(en)
|
2006-06-27 |
2010-09-14 |
Warner Chilcott Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US7589212B2
(en)
|
2006-06-27 |
2009-09-15 |
Procter & Gamble Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US8846685B2
(en)
|
2006-06-27 |
2014-09-30 |
Aerpio Therapeutics Inc. |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US10259860B2
(en)
*
|
2007-02-27 |
2019-04-16 |
Aprogen Inc. |
Fusion proteins binding to VEGF and angiopoietin
|
|
WO2008127727A1
(en)
|
2007-04-13 |
2008-10-23 |
Kinex Pharmaceuticals, Llc |
Biaryl compositions and methods for modulating a kinase cascade
|
|
JP2010531896A
(ja)
|
2007-06-26 |
2010-09-30 |
チルドレンズ メディカル センター コーポレーション |
治療的投与のためのＭｅｔＡＰ−２阻害剤ポリマーソーム
|
|
ES2540854T3
(es)
|
2007-06-29 |
2015-07-14 |
Merck Sharp & Dohme Corp. |
Usos de antagonistas MDL-1
|
|
JP2011500086A
(ja)
|
2007-10-22 |
2011-01-06 |
シェーリング コーポレイション |
完全ヒト抗ｖｅｇｆ抗体および使用方法
|
|
US9403789B2
(en)
|
2008-02-21 |
2016-08-02 |
Sequoia Pharmaceuticals, Inc. |
Benzofuran-containing amino acid inhibitors of cytochrome P450
|
|
US8293714B2
(en)
|
2008-05-05 |
2012-10-23 |
Covx Technology Ireland, Ltd. |
Anti-angiogenic compounds
|
|
BRPI0914251B1
(pt)
|
2008-06-25 |
2022-07-19 |
Novartis Ag |
Imunoligante recombinante, seu fragmento de ligação ao antígeno, uso dos mesmos, e composição
|
|
US8268314B2
(en)
*
|
2008-10-08 |
2012-09-18 |
Hoffmann-La Roche Inc. |
Bispecific anti-VEGF/anti-ANG-2 antibodies
|
|
BRPI0921469B1
(pt)
|
2008-11-03 |
2022-01-18 |
Molecular Partners Ag |
Proteínas de ligação que inibem a interação com o receptor de vegf-a, composição farmacêutica
|
|
DK2385763T3
(en)
|
2009-01-12 |
2018-07-16 |
Aerpio Therapeutics Inc |
METHODS OF TREATING VASCULAR LEAK SYNDROME
|
|
US9096555B2
(en)
|
2009-01-12 |
2015-08-04 |
Aerpio Therapeutics, Inc. |
Methods for treating vascular leak syndrome
|
|
ES2726946T3
(es)
|
2009-07-06 |
2019-10-10 |
Aerpio Therapeutics Inc |
Derivados de benzosulfonamida, composiciones de los mismos y su uso en la prevención de la metástasis de las células cancerosas
|
|
US8883832B2
(en)
|
2009-07-06 |
2014-11-11 |
Aerpio Therapeutics Inc. |
Compounds, compositions, and methods for preventing metastasis of cancer cells
|
|
RS54010B1
(sr)
|
2009-11-06 |
2015-10-30 |
Aerpio Therapeutics Inc. |
Inhibitori prolil hidroksilaze
|
|
AU2010325969B2
(en)
|
2009-12-02 |
2016-10-20 |
Imaginab, Inc. |
J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen
|
|
ES2468827T3
(es)
|
2010-01-14 |
2014-06-17 |
Sanwa Kagaku Kenkyusho Co., Ltd |
Producto farmacéutico para prevenir o tratar trastornos acompañados de angiog�nesis ocular y/o permeabilidad vascular ocular elevada
|
|
CA3253628A1
(en)
|
2010-03-05 |
2025-11-29 |
The Johns Hopkins University |
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
|
|
AR081361A1
(es)
|
2010-04-30 |
2012-08-29 |
Molecular Partners Ag |
Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
|
|
US20180092883A1
(en)
|
2010-10-07 |
2018-04-05 |
Aerpio Therapeutics, Inc. |
Phosphatase inhibitors for treating ocular diseases
|
|
NZ610230A
(en)
|
2010-10-07 |
2015-07-31 |
Aerpio Therapeutics Inc |
Compositions and methods for treating ocular edema, neovascularization and related diseases
|
|
KR20190049934A
(ko)
|
2011-01-13 |
2019-05-09 |
리제너론 파아마슈티컬스, 인크. |
혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
|
|
WO2013056240A1
(en)
|
2011-10-13 |
2013-04-18 |
Aerpio Therapeutics, Inc. |
Methods for treating vascular leak syndrome and cancer
|
|
BR112014008759A8
(pt)
|
2011-10-13 |
2017-09-12 |
Aerpio Therapeutics Inc |
Tratamento de doença ocular
|
|
ES2753135T3
(es)
|
2012-05-07 |
2020-04-07 |
Allergan Inc |
Método de tratamiento de DMAE en pacientes resistentes a terapia anti-VEGF
|
|
SG11201408538PA
(en)
|
2012-07-13 |
2015-02-27 |
Roche Glycart Ag |
Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
|
|
EP2890389A1
(en)
|
2012-08-28 |
2015-07-08 |
Novartis AG |
Use of a vegf antagonist in treating ocular vascular proliferative diseases
|
|
AU2014233363B2
(en)
|
2013-03-15 |
2017-06-29 |
EyePoint, Inc. |
Compositions, formulations and methods for treating ocular diseases
|
|
US20150050277A1
(en)
|
2013-03-15 |
2015-02-19 |
Aerpio Therapeutics Inc. |
Compositions and methods for treating ocular diseases
|
|
US10617755B2
(en)
|
2013-08-30 |
2020-04-14 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
|
CA2926853C
(en)
|
2013-10-18 |
2022-04-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
|
|
PT3065761T
(pt)
|
2013-11-05 |
2020-02-21 |
Allergan Inc |
Método de tratamento de condições oculares com um darpin anti-vegf
|
|
ES2866935T3
(es)
|
2014-01-10 |
2021-10-20 |
Anaptysbio Inc |
Anticuerpos dirigidos contra interleucina-33 (IL-33)
|
|
WO2015109898A1
(zh)
*
|
2014-01-24 |
2015-07-30 |
上海恒瑞医药有限公司 |
VEGF与PDGFRβ双特异性融合蛋白及其用途
|
|
US9719135B2
(en)
|
2014-07-03 |
2017-08-01 |
Mannin Research Inc. |
Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system
|
|
WO2016022813A1
(en)
|
2014-08-07 |
2016-02-11 |
Aerpio Therapeutics, Inc. |
Combination of immunotherapies with activators of tie-2
|
|
BR112017003263A2
(pt)
|
2014-09-16 |
2017-11-28 |
Ovascience Inc |
anticorpos anti-vasa, e métodos de produção e utilização dos mesmos
|
|
WO2016049183A1
(en)
|
2014-09-24 |
2016-03-31 |
Aerpio Therapeutics, Inc. |
Ve-ptp extracellular domain antibodies delivered by a gene therapy vector
|
|
TWI806150B
(zh)
|
2014-11-07 |
2023-06-21 |
瑞士商諾華公司 |
穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
|
|
CN114306575A
(zh)
|
2014-12-11 |
2022-04-12 |
拜耳医药保健有限责任公司 |
具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗
|
|
WO2016115092A1
(en)
|
2015-01-12 |
2016-07-21 |
La Jolla Institute For Allergy And Immunology |
Methods for targeting host vascular mechanism for therapeutic protection against hemorrhagic fever
|
|
AR103477A1
(es)
|
2015-01-28 |
2017-05-10 |
Lilly Co Eli |
Compuestos de vegfa / ang2
|
|
KR102427117B1
(ko)
|
2015-04-02 |
2022-07-29 |
몰리큘라 파트너스 아게 |
혈청 알부민에 대한 결합 특이성을 갖는 설계된 안키린 반복 도메인
|
|
US11091559B2
(en)
|
2015-08-27 |
2021-08-17 |
Celldex Therapeutics, Inc. |
Anti-ALK antibodies and methods for use thereof
|
|
PE20181363A1
(es)
|
2015-09-23 |
2018-08-27 |
Genentech Inc |
Variantes optimizadas de anticuerpos anti-vegf
|
|
US10894823B2
(en)
|
2016-03-24 |
2021-01-19 |
Gensun Biopharma Inc. |
Trispecific inhibitors for cancer treatment
|
|
WO2018007314A1
(en)
|
2016-07-04 |
2018-01-11 |
F. Hoffmann-La Roche Ag |
Novel antibody format
|
|
BR112019001206A2
(pt)
|
2016-07-20 |
2019-06-25 |
Aerpio Therapeutics Inc |
anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
|
|
MX2019003895A
(es)
|
2016-10-04 |
2019-10-07 |
Asclepix Therapeutics Inc |
Compuestos y metodos para activar la señalizacion tie2.
|
|
IT201600120314A1
(it)
|
2016-11-28 |
2018-05-28 |
Nuovo Pignone Tecnologie Srl |
Turbo-compressore e metodo di funzionamento di un turbo-compressore
|
|
US10426817B2
(en)
|
2017-01-24 |
2019-10-01 |
Macregen, Inc. |
Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics
|
|
US20200140547A1
(en)
|
2017-05-26 |
2020-05-07 |
The Johns Hopkins University |
Multifunctional antibody-ligand traps to modulate immune tolerance
|
|
TW201904610A
(zh)
|
2017-06-14 |
2019-02-01 |
德商拜耳製藥公司 |
用於治療新生血管型青光眼之非抗體vegf拮抗劑
|
|
CN107602702A
(zh)
|
2017-09-22 |
2018-01-19 |
生标（上海）医疗器械科技有限公司 |
一种同时靶向人p185和血管内皮生长因子的抗体及其应用
|
|
HUE059827T2
(hu)
|
2017-11-30 |
2023-01-28 |
Regeneron Pharma |
VEGF-antagonista alkalmazása angiogén szembetegségek kezelésére
|
|
EP3758735B1
(en)
|
2018-02-28 |
2023-12-13 |
AP Biosciences, Inc. |
Bifunctional proteins combining checkpoint blockade for targeted therapy
|
|
KR20200131839A
(ko)
|
2018-03-16 |
2020-11-24 |
노파르티스 아게 |
안질환의 치료 방법
|
|
US10276202B1
(en)
|
2018-04-23 |
2019-04-30 |
Western Digital Technologies, Inc. |
Heat-assisted magnetic recording (HAMR) medium with rhodium or rhodium-based alloy heat-sink layer
|
|
DK4364724T3
(da)
|
2018-05-10 |
2025-12-22 |
Regeneron Pharma |
Formuleringer med høj koncentration af VEGF-receptorfusionsprotein
|
|
CA3100349A1
(en)
|
2018-05-17 |
2019-11-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Receptor inhibition by phosphatase recruitment
|
|
US11066476B2
(en)
|
2018-09-14 |
2021-07-20 |
Shanghai tongji hospital |
Asymmetric bispecific antibody
|
|
WO2020068653A1
(en)
|
2018-09-24 |
2020-04-02 |
Aerpio Pharmaceuticals, Inc. |
MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
|